Literature DB >> 28765227

Determination of an Optimal Pharmacokinetic Model of 18F-FET for Quantitative Applications in Rat Brain Tumors.

Marie Anne Richard1, Jérémie P Fouquet1, Réjean Lebel1, Martin Lepage2.   

Abstract

O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) is a radiolabeled artificial amino acid used in PET for tumor delineation and grading. The present study compares different kinetic models to determine which are more appropriate for 18F-FET in rats.
Methods: Rats were implanted with F98 glioblastoma cells in the right hemisphere and scanned 9-15 d later. PET data were acquired during 50 min after a 1-min bolus of 18F-FET. Arterial blood samples were drawn for arterial input function determination. Two compartmental pharmacokinetic models were tested: the 2-tissue model and the 1-tissue model. Their performance at fitting concentration curves from regions of interest was evaluated using the Akaike information criterion, F test, and residual plots. Graphical models were assessed qualitatively.
Results: Metrics indicated that the 2-tissue model was superior to the 1-tissue model for the current dataset. The 2-tissue model allowed adequate decoupling of 18F-FET perfusion and internalization by cells in the different regions of interest. Of the 2 graphical models tested, the Patlak plot provided adequate results for the tumor and brain, whereas the Logan plot was appropriate for muscles.
Conclusion: The 2-tissue-compartment model is appropriate to quantify the perfusion and internalization of 18F-FET by cells in various tissues of the rat, whereas graphical models provide a global measure of uptake.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  FET; glioma; pharmacokinetic model

Mesh:

Substances:

Year:  2017        PMID: 28765227     DOI: 10.2967/jnumed.116.180612

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

1.  Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function.

Authors:  Guobao Wang; Michael T Corwin; Kristin A Olson; Ramsey D Badawi; Souvik Sarkar
Journal:  Phys Med Biol       Date:  2018-07-24       Impact factor: 3.609

2.  Multiparametric Cardiac 18F-FDG PET in Humans: Kinetic Model Selection and Identifiability Analysis.

Authors:  Yang Zuo; Ramsey D Badawi; Cameron C Foster; Thomas Smith; Javier E López; Guobao Wang
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2020-10-15

3.  Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma.

Authors:  Thomas Koopman; Niels Verburg; Robert C Schuit; Petra J W Pouwels; Pieter Wesseling; Albert D Windhorst; Otto S Hoekstra; Philip C de Witt Hamer; Adriaan A Lammertsma; Ronald Boellaard; Maqsood Yaqub
Journal:  EJNMMI Res       Date:  2018-07-31       Impact factor: 3.138

4.  Quantitative parametric maps of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma.

Authors:  Thomas Koopman; Niels Verburg; Petra Jw Pouwels; Pieter Wesseling; Otto S Hoekstra; Philip C De Witt Hamer; Adriaan A Lammertsma; Maqsood Yaqub; Ronald Boellaard
Journal:  J Cereb Blood Flow Metab       Date:  2019-05-24       Impact factor: 6.200

5.  Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation.

Authors:  Lena Vomacka; Marcus Unterrainer; Adrien Holzgreve; Erik Mille; Astrid Gosewisch; Julia Brosch; Sibylle Ziegler; Bogdana Suchorska; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Peter Bartenstein; Nathalie Lisa Albert; Guido Böning
Journal:  EJNMMI Res       Date:  2018-09-10       Impact factor: 3.138

6.  Feasibility and robustness of dynamic 18F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation.

Authors:  Charlotte Debus; Ali Afshar-Oromieh; Ralf Floca; Michael Ingrisch; Maximilian Knoll; Jürgen Debus; Uwe Haberkorn; Amir Abdollahi
Journal:  Sci Rep       Date:  2018-10-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.